Roland Sackers Chief Financial Officer September 19, 2012 · review QIAGEN’s press releases,...

Sample & Assay Technologies

UBS Global Life Sciences ConferenceRoland Sackers Chief Financial OfficerSeptember 19, 2012

Sample & Assay Technologies Forward looking statements

Safe Harbor Statement: Certain of the statements contained in this presentation may be considered forward-lookingstatements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S.Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating toQIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, areforward-looking, such statements are based on current expectations and assumptions that involve a number ofuncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management ofgrowth and international operations (including the effects of currency fluctuations, regulatory processes and dependenceon logistics), variability of operating results and allocations between business segments, the commercial development ofmarkets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPVtesting and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategicpartners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products(including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and otherfactors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products tointegrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and todifferentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and theintegration of acquired technologies and businesses. For further information, please refer to the discussions in reports thatQIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Regulation G: Some of the slides in this presentation contain certain summary information about QIAGEN N.V.’s sales,gross profit, operating income, net income, and earnings per share, which information is presented on a “non-GAAPfinancial measures” basis rather than in accordance with U.S. generally accepted accounting principles (GAAP). Pleasereview QIAGEN’s press releases, which can be found in the Investor Relations section of QIAGEN’s webpage underwww.QIAGEN.com, for information on the Company’s operating income, net income, and earnings per share presented ona GAAP basis. Such GAAP-basis information will also be contained in the Company’s reports on Form 20-F or Form 6-K tobe filed with or furnished to the U.S. Securities and Exchange Commission.

2


33

Broad product offering with common purpose

From biological sample to clinical result

3

SAMPLE Technologies ASSAY TechnologiesBIOLOGICAL SAMPLE

VALUABLE MOLECULAR

INFORMATION


44

World leader in Sample & Assay Technologies

Enable access to molecular information Biological sample to digital result

> 500 core products Consumable kits and instruments

> 500,000 customers worldwide Molecular Diagnostics Applied Testing Pharma Academia

Innovative power ~2,500 patents

Healthy financial position Strong cash conversion Improving margins

2011 key figures (In $ millions)

Net sales 1,169 + 4% (CER)

Adjusted operating income 319.6 +4%

Adjusted net income 234.4 +5%

Employees ~3,900

4

CER – Constant exchange rates


5

Instruments

Products for use with kits Automating entire workflows Many detection technologies

Real-time PCR Pyrosequencing Isothermal amplification Hybrid capture

Consumables

> 500 core product groups Specialized kits with all

materials > 90% of products sold to

more than one customer class

85%15%

Comprehensive product range to support workflows

2011 net sales

5


66

Operating in attractive markets

6

Applied Testing Pharma AcademiaMolecular Diagnostics

2011 sales($1,169.7 m)

~47%(Other MDx: ~32%)(U.S. HPV: ~15%)

~7% ~20% ~26%

Long-term growth opportunities +++ +++ ++ +Key customers Reference labs

Hospitals

Forensic labs

Industrial

Government agencies

Big Pharma

Specialty / Biotech

CROs

Government research

Academic and private labs

Highlights Personalized Healthcare

Virology

QuantiFERON

HPV

Forensics

Vet and food safety portfolio

GeneGlobe:Pathway analysis

Biomarkers

Trusted brand

Involvement with breakthroughs

Translational research


77

Strategic initiatives to drive growth and innovation

Drive platform success Roll out QIAsymphony worldwide Advance QIAensemble strategy

Leverage leadership in Sample & Assay Technologies

7

Add content New tests across all customer classes

Broaden geographic presence Target high-growth emerging markets

Grow efficiently and effectively Sustained growth and improved profitability Leverage synergies across customer classes Best-in-class team and work environment

Molecular Diagnostics

Applied Testing

Pharma

Academia

Sample & Assay Technologies Focusing on multiple growth drivers

Investing in rapid growth Profiling: Molecular testing of active diseases QuantiFERON-TB: New standard for latent TB PHC: Leadership in companion diagnostics AmniSure: Critical end-of-pregnancy test

Maximizing value HPV: Leverage U.S. leadership, expand globally Strategic foundation for expansion

MDxgrowth drivers

Pharma

Academia

Applied Testing

HPV(U.S. 14%)

~30% of net sales+46% CER

~17% of net sales-6% CER

(Rest of world 4%)





Creating new opportunities Applied Testing: Forensics, food and vet testing Pharma: Gene-based R&D Academia: Translational medicine

H1 2012 sales: $603.6 million (+14% CER)


Molecular Diagnostics

Life Sciences

8

Sample & Assay Technologies QIAsymphony RGQ: New era of automation

Most versatile molecular testing system

On track for >200 new placements in 2012 End-2011 level: >550 systems Rising average consumables pull-through

Global rollout gaining momentum Component approvals in U.S. and China

Improving value proposition Software update in Q2 2012 Protocols for companion diagnostics

Development projects in all customer classes

QIAsymphony SP Automates sample prep

QIAsymphony AS Automates assay setup

Sample Result

Rotor-Gene Q Detection Analysis

QIAsymphony family

9

QIAGEN addressing needs for lab automation and integration

Sample & Assay Technologies Adding content to QIAGEN portfolio

Selected regulatory projects Type Status

Rotor-Gene Q MDx Real-time PCR thermocycler instrument 510(k)

artus Influenza A/B Influenza test for use on Rotor-Gene Q MDx 510(k)

therascreen KRAS (Erbitux) Companion diagnostic for Erbitux in metastatic colorectal cancer PMA

therascreen KRAS (Vectibix) Companion diagnostic for Vectibix in metastatic colorectal cancer PMA Submitted H2 2011

careHPV Low-cost HPV test for developing countries sFDA Submitted H2 2011

artus CT/NG Chlamydia (CT) and gonorrhea (GC) CE IVD Planned 2012 submission

artus CMV Cytomegalovirus (CMV) infections in transplant patients PMA Planned 2012

submission

QuantiFERON CMV Cytomegalovirus (CMV) infections in transplant patients 510(k) Planned 2012

submission

therascreen EGFR Companion diagnostic in non-small cell lung cancer (NSCLC) PMA Planned 2012

submission

therascreen BRAF Biomarker test for melanoma CE IVD Planned 2012 submission

10

Sample & Assay Technologies All stakeholders benefit from Personalized Healthcare

Payors Cost savings

Physicians Confidence in decisions

Patients Better medicines

Pharma companies Value creation

Providers of diagnostics New market opportunities

11


Only FDA-approved KRAS test for use in metastatic CRC patients Erbitux now a first-line treatment

U.S. launch underway after July 2012 approval Drive commercial test adoption Campaigns targeting pathologists, oncologists and patients

Building portfolio on Rotor-Gene Q MDx Broadest range of companion diagnostics Automation with QIAsymphony Attractive economics to laboratories

FDA KRAS approval marks entry into attractive U.S. market

Sample & Assay Technologies Expanding lead in Personalized Healthcare

Milestone: U.S. approval of therascreen KRAS test

therascreenKRAS

positive

therascreenKRAS

negative

12

Sample & Assay Technologies Leading co-development project portfolio

Selected Personalized Healthcare co-development projects

Project Partner Indication Biomarker Status

Eribitux (cetuximab)

Colorectalcancer KRAS Approved in July 2012

Vectibix (panitumumab)

Colorectalcancer KRAS Submitted U.S.

(PMA) in H2 2011

PF-00299804(dacomitinib)

Lung cancer(NSCLC) KRAS In development

Iressa (gefitnib)

Lung cancer(NSCLC) EGFR CE-IVD kit in Europe and

other non-U.S. markets

(afatinib)Lung cancer(NSCLC) EGFR U.S. submission planned

for 2012

Early-stage compound Blood cancer JAK2 In development

Not disclosed Confidential partners Oncology and non-oncology Various In development

Partner of choice: Industry-leading 15 projects under way

13

Sample & Assay Technologies QuantiFERON TB-Gold: New global test standard

Latent TB testing required in developed countries

Single visit Higher cost per diagnostic test (~$20 / test)

But lower overall costs (One doctor visit, etc.)

High specificity: 99.2% No impact from TB vaccination (BCG)

Two visits required within 48–72 hours Lower cost per diagnostic test (~$5-10 / test)

But significant follow-up costs (Doctor visits, high false-positive rate, etc.)

Low specificity: 65.9% Not reliable for TB-vaccinated people

Tuberculosis Skin Test (TST)QuantiFERON-TB Gold

Publichealth

Employmentscreening

Communitylivingsurveillance

Immuno-suppressedpatients

Clinicaltrials

Treatment infoHIV Rheumatoid arthritisDiabetesRenal diseaseCancer

Correctional sitesPrisonsState / local jails

Medical staffHealthcare workersNursing homes Social workers

TB controlContact checksTB clinics

Patient selectionSafety dataEfficacy profile

Latent TB customer groups

14

Sample & Assay Technologies Expanding geographic presence

Full-year 2011 net sales by region

Targeting expansion in Eastern Europe and Latin America

48%

34%

17%Asia-Pacific / Japan+8% CER

Europe / Middle East / Africa+7% CER

Americas+2% CER

Brazil Russia Future opportunityIndia 2011 direct entryChina South Korea Turkey Mexico

Top 7 emerging markets:12% of net sales / +21% CER

CER – Constant exchange ratesEMEA – Europe / Middle East / Africa

15


QIAsymphony global rollout Test menu expansion

Companion diagnostics U.S. market approvals Translational medicine Applied Testing

High-growth markets

Freeing up resources to reinvest

Returning QIAGEN to a faster growth profile

Reallocate resources and personnel, selective reductions

Project planning Restructuring charge1

Implementing projects: R&D portfolio Manufacturing Pricing optimization Global procurement Organizational

excellence Restructuring charge1

Completed Ongoing

Efficiency gains(Q4 2011 – Q1 2012)

Operational improvements(Start: Q1 2012)P

hase

Topi

csS

tatu

s

Selected investments

2012 goal: Free up $50 million to reinvest in strategic initiatives

1 Restructuring charges of $75 million taken in Q4 2011 and $11 million in Q1 2012, further charges may be taken in 2012

16


Gross margin+Site

consolidation- Product mix

+ Pricing strategy

+ Procurement

Levers to improve adjusted operating margin

Adjusted operating income margin overview

2011actual

27%(Q4: 29%)

2013target

>29%(Q4: >31%)

Gross margin

R&D

2012target

~27-28%(Q4: ~30%)

SG&A+ Sales models

+ Shared services

+ Procurement

+Streamlined portfolio

- Clinical trials

+ Procurement

- Product mixInstruments(QIAsymphony) HPV

- CDx deals

- Post-acquisition investments

+ Pricing strategy

SG&A+ Sales models

+ Shared services

+ Procurement

R&D

+Portfolio focus

+ Procurement

17


Track record of growth and innovation

Robust development pipeline Strong free cash flow

World leader in Sample & Assay Technologies

Driving the dissemination of molecular testing

Key considerations: Strong growth potential

Attractive and growing markets

Building leadership in Molecular Diagnostics Highly competitive offering in Academia, Pharma and Applied Testing

Capitalizing on diverse growth opportunities

Pioneer in Personalized Healthcare Expansion into high-growth markets

18


Thank you!

19

Roland Sackers Chief Financial Officer September 19, 2012 · review QIAGEN’s press releases,...

Documents

Transcript of Roland Sackers Chief Financial Officer September 19, 2012 · review QIAGEN’s press releases,...